Royal Bank Of Canada Zymeworks Inc. Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $157,551 - $251,743	33,882 New	33,882 $208,000
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $112,578 - $318,595	-18,763 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $17,772 - $34,316	-1,170 Reduced 5.87%	18,763 $307,000
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $38,536 - $52,527	1,409 Added 7.61%	19,933 $579,000
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $490,886 - $708,172	18,524 New	18,524 $643,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.